364 related articles for article (PubMed ID: 19924695)
21. [Pathological mechanisms of Parkinson's disease].
Matsui H; Takahashi R
Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
[TBL] [Abstract][Full Text] [Related]
22. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system.
Betarbet R; Canet-Aviles RM; Sherer TB; Mastroberardino PG; McLendon C; Kim JH; Lund S; Na HM; Taylor G; Bence NF; Kopito R; Seo BB; Yagi T; Yagi A; Klinefelter G; Cookson MR; Greenamyre JT
Neurobiol Dis; 2006 May; 22(2):404-20. PubMed ID: 16439141
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.
Elkon H; Melamed E; Offen D
J Mol Neurosci; 2004; 24(3):387-400. PubMed ID: 15655261
[TBL] [Abstract][Full Text] [Related]
24. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
25. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
26. Parkinson disease: from pathology to molecular disease mechanisms.
Dexter DT; Jenner P
Free Radic Biol Med; 2013 Sep; 62():132-144. PubMed ID: 23380027
[TBL] [Abstract][Full Text] [Related]
27. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease.
McNaught KS; Olanow CW
Ann Neurol; 2003; 53 Suppl 3():S73-84; discussion S84-6. PubMed ID: 12666100
[TBL] [Abstract][Full Text] [Related]
28. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
29. Nuclear localization of the 20S proteasome subunit in Parkinson's disease.
Nakamura A; Kitami T; Mori H; Mizuno Y; Hattori N
Neurosci Lett; 2006 Oct; 406(1-2):43-8. PubMed ID: 16911859
[TBL] [Abstract][Full Text] [Related]
30. Does proteasome [corrected] inhibition decrease or accelerate toxin-induced dopaminergic neurodegeneration?
Setsuie R; Kabuta T; Wada K
J Pharmacol Sci; 2005 Mar; 97(3):457-60. PubMed ID: 15764834
[TBL] [Abstract][Full Text] [Related]
31. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
[TBL] [Abstract][Full Text] [Related]
32. Does autophagy worsen or improve the survival of dopaminergic neurons?
Pasquali L; Ruggieri S; Murri L; Paparelli A; Fornai F
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S24-7. PubMed ID: 20123552
[TBL] [Abstract][Full Text] [Related]
33. Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease.
Ambrosi G; Ghezzi C; Sepe S; Milanese C; Payan-Gomez C; Bombardieri CR; Armentero MT; Zangaglia R; Pacchetti C; Mastroberardino PG; Blandini F
Biochim Biophys Acta; 2014 Sep; 1842(9):1385-94. PubMed ID: 24854107
[TBL] [Abstract][Full Text] [Related]
34. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study.
Kingsbury AE; Marsden CD; Foster OJ
Mov Disord; 1999 Mar; 14(2):206-18. PubMed ID: 10091611
[TBL] [Abstract][Full Text] [Related]
35. Neurodegenerative pathways in Parkinson's disease: therapeutic strategies.
Cardoso SM; Moreira PI; Agostinho P; Pereira C; Oliveira CR
Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):405-19. PubMed ID: 16101557
[TBL] [Abstract][Full Text] [Related]
36. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity.
Shamoto-Nagai M; Maruyama W; Hashizume Y; Yoshida M; Osawa T; Riederer P; Naoi M
J Neural Transm (Vienna); 2007; 114(12):1559-67. PubMed ID: 17690948
[TBL] [Abstract][Full Text] [Related]
37. Noradrenergic lesion of the locus coeruleus increases apomorphine-induced circling behavior and the firing activity of substantia nigra pars reticulata neurons in a rat model of Parkinson's disease.
Wang Y; Zhang QJ; Liu J; Ali U; Gui ZH; Hui YP; Chen L; Wu ZH; Li Q
Brain Res; 2010 Jan; 1310():189-99. PubMed ID: 19896932
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures.
Reaney SH; Johnston LC; Langston WJ; Di Monte DA
Exp Neurol; 2006 Dec; 202(2):434-40. PubMed ID: 16920101
[TBL] [Abstract][Full Text] [Related]
39. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Damier P; Hirsch EC; Agid Y; Graybiel AM
Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
[TBL] [Abstract][Full Text] [Related]
40. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.
Li C; Guo Y; Xie W; Li X; Janokovic J; Le W
Neurochem Res; 2010 Oct; 35(10):1546-56. PubMed ID: 20635141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
